Shopping Cart
- Remove All
- Your shopping cart is currently empty
CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | 38 € | In Stock | |
25 mg | 77 € | In Stock | |
50 mg | 126 € | In Stock | |
100 mg | 191 € | In Stock | |
1 mL x 10 mM (in DMSO) | 30 € | In Stock |
Description | CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer. |
In vitro | CT52923 inhibits PDGFRs and stem cell factor receptors with IC50 values of 100 to 200 nM. CT52923(0.01-30 μ M; 24 h) blocks smooth muscle cell migration or fibroblast proliferation induced by platelet-derived growth factor, IC50 is 64 and 280 nM respectively [1]. |
In vivo | CT52923 (oral; 5,15,30 and 50 mg/kg; twice daily) significantly inhibits the formation of neointima after carotid artery injury in rats [1]. |
Molecular Weight | 467.54 |
Formula | C23H25N5O4S |
Cas No. | 205256-55-9 |
Smiles | COc1cc2ncnc(N3CCN(CC3)C(=S)NCc3ccc4OCOc4c3)c2cc1OC |
Relative Density. | 1.370 g/cm3 (Predicted) |
Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 60 mg/mL (128.33 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.